Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stake Boosted by Ieq Capital LLC

Ieq Capital LLC raised its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 65.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,853 shares of the medical equipment provider’s stock after purchasing an additional 3,904 shares during the period. Ieq Capital LLC’s holdings in Zimmer Biomet were worth $1,041,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares during the period. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet in the fourth quarter worth about $25,000. Ashton Thomas Securities LLC acquired a new position in Zimmer Biomet in the third quarter valued at approximately $28,000. Brooklyn Investment Group bought a new position in shares of Zimmer Biomet during the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $39,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 1.1 %

ZBH stock opened at $106.00 on Tuesday. The firm has a market cap of $21.10 billion, a PE ratio of 23.82, a P/E/G ratio of 1.95 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a 50 day simple moving average of $105.85 and a 200 day simple moving average of $107.44.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter in the prior year, the firm posted $2.20 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were paid a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.91%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ZBH. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Wells Fargo & Company lifted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Stifel Nicolaus lifted their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.